Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Generalized Anxiety Disorder
Interventions: Applied relaxation and self-control desensitization, Cognitive therapy (CT), Cognitive-Behavioral Therapy; Behavioral · Other
Lead sponsor: Michelle G. Newman; Other
Eligibility: 18 Years to 85 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 1998
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Heart Diseases, Coronary Artery Disease, Chest Pain, Stenosis Coronary, STEMI
Interventions: TEE probe; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sun Protection
Interventions: SunBeast Educational module, Control; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Bladder Outlet Obstruction, BPH
Interventions: High Intensity Focused Ultrasound; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Luminex Corporation; Industry
Eligibility: 1 Day to 7 Days
Enrollment: 7,462 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Albany, New York • Nashville, Tennessee • Taylorsville, Utah

Conditions: Arterial Stiffness
Interventions: Fish Oil; Dietary Supplement
Lead sponsor: Salisbury University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salisbury, Maryland

Conditions: Lymphoma
Interventions: epratuzumab, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 162
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 102 more

Conditions: Inguinal Hernia
Interventions: Mastery Learning TEP Curriculum, Current Practice; Behavioral · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Early-Stage Breast Cancer
Interventions: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Falls
Interventions: Mulit-modality Balance Intervention, Gerofit; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Interventions: total body irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine, Clofarabine, (CliniMACS) T-cell depleted PBSC Transplant; Radiation · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 69 Years
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Upper Gastrointestinal Motility Disorders
Interventions: Not listed
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 10 Years to 18 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Complete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Syndrome
Interventions: Cultured Thymus Tissue; Biological
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Neoplasms, Breast Neoplasms
Interventions: Chi gung: Stay Well, Live Well; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: New York, New York

Conditions: Airway Management, Respiration, Artificial
Interventions: Adult Sotair Device; Device
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Neoplasms, Neoplasms, Ovarian, Neoplasms, Breast, Advanced or Refractory Solid Malignancies
Interventions: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB, DOXIL/CAELYX (doxorubicin) Treatment Sequence BA; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Chronic Rhinitis, Non-allergic Rhinitis
Interventions: RhinAer, Neuromark, Clarifix; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Interventions: FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo; Dietary Supplement
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 62 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vascular Lesions, Photoaging
Interventions: velos; Device
Lead sponsor: Syneron Medical; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: San Diego, California • Wayland, Massachusetts • Edina, Minnesota + 1 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Defense and Veterans Center for Integrative Pain Management; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma
Interventions: filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 80
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 60 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: IVR Intervention Group; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 1,270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Oakland, California

Conditions: Pancreatic Cancer
Interventions: Intravenous Vitamin C, Gemcitabine; Drug
Lead sponsor: Jeanne Drisko, MD, CNS, FACN; Other
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: prednisone, vincristine sulfate, daunorubicin hydrochloride, asparaginase, methotrexate, cyclophosphamide, cytarabine, mercaptopurine, leucovorin calcium, dexamethasone, doxorubicin hydrochloride, thioguanine, radiation therapy, nelarabine, pegaspargase, pharmacological study, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Arcadia, California

Search by objective public record fields.

A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder

Intraoperative Echocardiography in Low-Risk CABG Surgery

SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners

High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction

Clinical Evaluation of NeoPlex4 Assay and NeoPlex System

Minimum Time Effect of Fish Oil on Arterial Stiffness

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Mastery Learning Inguinal Hernia Repair

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Targeting the Hip Abductors to Reduce Falls in Older Veterans Through A Virtual Multimodal Balance Intervention

HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

Use of an Ambulatory Capsule to Characterize Gastrointestinal Pressure Patterns in Children

Thymus Transplantation Safety-Efficacy

Increasing Breast and Colorectal Cancer Screening in the Community

Superiority Trial Between Sotair® Device Attached to Manual Resuscitator Versus Ventilation Alone

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

A Randomized Controlled Trial Comparing Posterior Nasal Nerve Ablation Procedures for Chronic Rhinitis

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

VELOS for the Treatment of Vascular Lesions and Skin Rejuvenation

Regional Anesthesia Versus General Anesthesia on Circulating Tumor Cells (CTC)

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy

New Treatment Option for Pancreatic Cancer

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia